Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GHTF's (Global Harmonisation Task Force's) Who's Who updated:

This article was originally published in Clinica

Executive Summary

The Global Harmonisation Task Force (GHTF) has just published on its website an updated Steering Committee membership list. The list contains contact details for all the members, including those recently appointed: Claude Ghislain, head of medical device at the French agency for healthcare product safety (AFSSaPS); and Jos Klaus, a senior inspector with the Dutch medical device competent authority. There are representatives on the Steering Committee from both industry and regulatory authorities in each of the five founding members of the GHTF: the EU (which currently has the chairmanship), Asia-Pacific, Australia, Canada and the US. Also listed are details of the recently confirmed study group chairs (see Clinica No 1115, p 12) and of the two secretariats: Ronda Balham at the US Center for Devices and Radiological Health; and Susanne Hoke, at the European Commission's unit responsible for medical devices.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts